The dopamine stabilizers (S)-(-)-(3-methanesulfonyl-phenyl)-1-propyl-piperidine [(-)-OSU6162] and 4-(3-methanesulfonylphenyl)-1-propyl-piperidine (ACR16) show high in vivo D2 receptor occupancy, antipsychotic-like efficacy, and low potential for mot

The dopamine stabilizers (S)-(-)-(3-methanesulfonyl-phenyl)-1-propyl-piperidine [(-)-OSU6162] and 4-(3-methanesulfonylphenyl)-1-propyl-piperidine (ACR16) show high in vivo D2 receptor occupancy, antipsychotic-like efficacy, and low potential for mot

Item

http://www.wikidata.org/entity/Q34519377

Q34519377

about

The tetrahydroisoquinoline derivative SB269,652 is an allosteric antagonist at dopamine D3 and D2 receptors Update on the Mechanism of Action of Aripiprazole: Translational Insights into Antipsychotic Strategies Beyond Dopamine Receptor Antagonism c-Fos identification of neuroanatomical sites associated with haloperidol and clozapine disruption of maternal behavior in the rat.Analysis of the actions of the novel dopamine receptor-directed compounds (S)-OSU6162 and ACR16 at the D2 dopamine receptor.II. In vitro evidence that (-)-OSU6162 and (+)-OSU6162 produce their behavioral effects through 5-HT2A serotonin and D2 dopamine receptors.I. In vivo evidence for partial agonist effects of (-)-OSU6162 and (+)-OSU6162 on 5-HT2A serotonin receptors.Effects of (-)-OSU6162 and ACR16 on motor activity in rats, indicating a unique mechanism of dopaminergic stabilization.Third generation antipsychotic drugs: partial agonism or receptor functional selectivity?The dopamine stabilizer (-)-OSU6162 occupies a subpopulation of striatal dopamine D2/D3 receptors: an [(11)C]raclopride PET study in healthy human subjects The effects of the dopamine stabilizer (-)-OSU6162 on aggressive and sexual behavior in rodents Dopamine and Huntington's disease.Pridopidine for the treatment of Huntington's disease.Pridopidine, a dopamine stabilizer, improves motor performance and shows neuroprotective effects in Huntington disease R6/2 mouse model.Profile of pridopidine and its potential in the treatment of Huntington disease: the evidence to date.Pridopidine selectively occupies sigma-1 rather than dopamine D2 receptors at behaviorally active doses.Metoprolol-pridopidine drug-drug interaction and food effect assessments of pridopidine, a new drug for treatment of Huntington's disease.The monoamine stabilizer (-)-OSU6162 counteracts downregulated dopamine output in the nucleus accumbens of long-term drinking Wistar rats.The dopaminergic stabilizer pridopidine increases neuronal activity of pyramidal neurons in the prefrontal cortex.The pridopidine paradox in Huntington's disease.Tolerability and efficacy of the monoaminergic stabilizer (-)-OSU6162 (PNU-96391A) in Huntington's disease: a double-blind cross-over study.Early pridopidine treatment improves behavioral and transcriptional deficits in YAC128 Huntington disease mice.The Effects of the Monoamine Stabilizer (-)-OSU6162 on Binge-Like Eating and Cue-Controlled Food-Seeking Behavior in Rats.Safety and Exploratory Efficacy at 36 Months in Open-HART, an Open-Label Extension Study of Pridopidine in Huntington's Disease.The dopaminergic stabilizers pridopidine and ordopidine enhance cortico-striatal Arc gene expression.Pridopidine Reverses Phencyclidine-Induced Memory Impairment.Pridopidine: Overview of Pharmacology and Rationale for its Use in Huntington's Disease.

P2860

Q24605967-DEF674D9-B144-4555-946F-E4801D693AA9 Q28084069-A3A03C0F-BE18-4356-AD67-72221370BF12 Q33725056-CE7A48BE-1EDB-4D78-B104-7CF986CD7B9C Q34134875-C922C78B-8C9F-45D0-B16C-ACB24C3F2F27 Q34210759-9623FB01-6E7F-43A1-9C49-F8AE8094405D Q34211486-8A35E674-ADE0-4AC9-9C58-BC06F715CC12 Q34763003-F4516C67-AB1C-4C1E-A1AD-F42C7CDE88EE Q35012574-1FFE51D4-75F5-4EDD-9A46-800A187BDE2D Q35647369-6DCC14D2-45DC-4D87-AE86-CF2E6463FD27 Q36915486-2A499A50-3344-493D-87F6-54E81881F5D9 Q38379277-21A31432-DDF1-48EE-8B0F-186D74C5F603 Q38735562-E570A2AF-65ED-4A34-918C-DB36ABC32DEF Q38861728-C69A000A-6405-4240-BB52-AA12595ADA2A Q40277912-471E47EB-D1ED-49EC-AB2C-A586BCF8ADA3 Q40753593-C8315295-6DFE-447A-B27C-B3D51EBBF7B9 Q41196024-65645758-9C2E-4FA9-9521-349DC888E570 Q41392387-1E4DB7B6-321F-4379-B54E-74F44FEBDA66 Q42435280-A52B4FE0-F050-4716-83FD-41839D5A7F95 Q45294030-116F553F-4D82-4624-8712-5FDA33173562 Q45301837-621B747E-6F4D-44F7-9629-D1F3F8916C3C Q45305901-B234F718-54F9-450D-8E79-CD1D7ECED49A Q47321455-F1A293AE-4101-4E06-A5DF-F906BD4B072D Q47694898-850E4EEB-0873-4DB2-9256-9614921ED1CA Q51088282-3F86268A-C44B-45BA-83FB-411E54030AD3 Q52564664-AA708548-99CC-4EAE-BC36-F1E44832FF24 Q52685691-668FE8CD-8ACF-4FA3-83B9-FB2AE2AB0558

P2860

The dopamine stabilizers (S)-(-)-(3-methanesulfonyl-phenyl)-1-propyl-piperidine [(-)-OSU6162] and 4-(3-methanesulfonylphenyl)-1-propyl-piperidine (ACR16) show high in vivo D2 receptor occupancy, antipsychotic-like efficacy, and low potential for mot

Item

http://www.wikidata.org/entity/Q34519377

description

2006 nî lūn-bûn

@nan

2006 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu